Sklip

Skin cancer is one of the most rapidly growing cancers worldwide, and early detection and diagnosis is crucial to reducing both morbidity and mortality, particularly for malignant melanoma. Yet, despite advances in medical technology, the process remains complex and time-consuming. Founded in 2017, Sklip is revolutionizing skin cancer detection by providing healthcare providers and patients with access to fast, accurate, and comprehensive skin cancer triage and diagnosis, and consumers with access to skin cancer screening. At the heart of our innovation is Sklip AI, our proprietary image-based artificial intelligence. Built on the global standard of care—dermoscopy—Sklip AI offers the highest reported clinical utility accuracy for skin cancer triage in the industry. What further set us apart is our use of proprietary biopsy tissue marking AI in our laboratories, which will provide full context and actionable insights to both healthcare providers and pathology laboratories, reduce tissue sampling bias, yield higher accuracy, and lessen delayed / inaccurate diagnoses. Sklip is poised to become the first company in the U.S. to offer both advanced digital health AI for skin cancer triage and integrated dermatology-specific pathology laboratory diagnostic services—creating a seamless, end-to-end solution for skin cancer detection and diagnosis. With our technology, we aim to address a critical gap in the healthcare system and drive significant improvements in early skin cancer detection and diagnosis. Join us in our mission to save lives and transform the future of skin cancer care.